Novartis Acquires IFM Due to Develop First-In-Class STING Antagonist Program ... - BioSpace

Retrieved on: 2024-03-13 20:16:43

Tags for this article:

Immune system

IFM Therapeutics

Novartis

CGAS–STING cytosolic DNA sensing pathway

Cyclic GMP-AMP synthase

Stimulator of interferon genes

IFM

Inflammation

Atlas Venture

Inflammatory cytokine

Boston

Click the tags to see associated articles and topics

Novartis Acquires IFM Due to Develop First-In-Class STING Antagonist Program ... - BioSpace. View article details on HISWAI: https://www.biospace.com/article/releases/novartis-acquires-ifm-due-to-develop-first-in-class-sting-antagonist-program-targeting-innate-immune-system/

Excerpt

IFM Therapeutics (IFM) is a privately held biopharmaceutical company based in Boston, Massachusetts and financed by Atlas Venture, Abingworth, and ...

Article found on: www.biospace.com

View Original Article